CN103211948A - Compound preparation for treating primary osteoporosis and preparation method - Google Patents
Compound preparation for treating primary osteoporosis and preparation method Download PDFInfo
- Publication number
- CN103211948A CN103211948A CN2012100200051A CN201210020005A CN103211948A CN 103211948 A CN103211948 A CN 103211948A CN 2012100200051 A CN2012100200051 A CN 2012100200051A CN 201210020005 A CN201210020005 A CN 201210020005A CN 103211948 A CN103211948 A CN 103211948A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound preparation
- bone
- fructus
- primary osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the traditional Chinese medicine field, and relates to a traditional Chinese medicine preparation for treating primary osteoporosis and a preparation method. The compound preparation follows a therapeutic principle of nourishing kidney yin, and employs water extracts of wolfberry, cornus officinalis, Chinese yam, semen cuscutae, deerhorn glue, glue of tortoise plastron, big rehmanniae vaporata, ligustrum lucidum and by mixing with an auxiliary material, the above materials are pelletized and performed with tabletting to prepare the compound preparation. The result of the animal experiments shows that the compound preparation bone resorption and bone formation with high level due to ovariectomy can be reduced, a balance state that the bone formation is greater than the bone resorption can be recovered, and the bone mass is increased; osteocalcin secretion can be promoted, so that the lipoblast differentiation capability can be inhibited. The compound preparation can improve the symptom of primary osteoporosis, reduce recurrence and consolidate curative effect; and can avoid the inconvenience of temporary decoction and easy deterioration for long-term placing before administration of a traditional Chinese medicine decoction for the patients.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of compound preparation and preparation method for the treatment of primary osteoporosis.
Background technology
Prior art discloses osteoporosis, and (Osteoporosis is to reduce with the bone amount OP), and the fragility of bone increases, so that a kind of general skeletal diseases of fracture takes place.The present clinical very good medicine that still do not have.Though the hormones alternative medicine can reach certain therapeutic effect, many side effect have been produced simultaneously.In recent years, discover that Chinese medicine is showing certain advantage aspect the treatment osteoporosis.
Chinese medicine belongs to osteoporosis " atrophic debility of bones " " rheumatism involving the bone " category, and thinking suffers from a deficiency of the kidney is the basic reason that osteoporosis takes place, and adopts the Therapeutic Method of the kidney invigorating will obtain clinical therapeutic efficacy preferably.
Bolus as a Kidney-Yin-Tonic comes from the Jing-Yue Complete Works of Ming Dynasty famous expert Zhang Jingyue, and Bolus as a Kidney-Yin-Tonic is the representative prescription of nourishing kidney yin.Studies show that Bolus as a Kidney-Yin-Tonic is by the LIUWEI DIHUANG WAN plus-minus, has the representative side of nourishing kidney yin, is intended to " treating YIN within YANG ".Existing a large amount of clinical report, obtained good curative effect with Bolus as a Kidney-Yin-Tonic treatment osteoporosis, but still have following deficiency in medical practice: curative effect need be consolidated, and reduces recurrence as far as possible, need interim the decoction before Chinese medicine decoction is taken, put for a long time and easily mouldly lose rotten and make troubles or the like to the patient.
Summary of the invention
The object of the present invention is to provide the compound Chinese medicinal preparation of a kind of determined curative effect, safe treatment primary osteoporosis.
Chinese medicine belongs to osteoporosis " atrophic debility of bones " " rheumatism involving the bone " category, and thinking suffers from a deficiency of the kidney is the basic reason that osteoporosis takes place, and prior art adopts the Therapeutic Method of the kidney invigorating to obtain effect preferably.The representative prescription Bolus as a Kidney-Yin-Tonic that the present invention is based on warming and recuperating the kidney-YANG has obtained on the basis of good curative effect in the treatment osteoporosis, adopt tonifying kidney-yin side on the original side's of Bolus as a Kidney-Yin-Tonic basis, to add and subtract improvement, the present invention adopts Chinese crude drug: Fructus Lycii, Fructus Corni, Rhizoma Dioscoreae, Semen Cuscutae, Colla cornus cervi, Colla Plastri Testudinis, big Radix Rehmanniae Preparata, Fructus Ligustri Lucidi, its extract of Radix Polygoni Multiflori Preparata are that active component and pharmaceutical carrier are made compound preparation.
Chinese medicine quality of medicinal material involved in the present invention all should meet each pertinent regulations under corresponding medical material item of Chinese Pharmacopoeia version in 2010.Wherein,
Fructus Lycii is the dry mature fruit of plant of Solanaceae lycium barbarum LyciumbarbarumL..
Fructus Corni is the drying and ripening sarcocarp of Cornaceae plant Fructus Corni CornusofficinalisSieb.etZucc..
Rhizoma Dioscoreae is the dry rhizome of Dioscoreaceae plant Rhizoma Dioscoreae DioscoreaoppositaThunb..
Semen Cuscutae is the dry mature seed of convolvulaceous plant south Semen Cuscutae CuscutaaustralisR.Br. or Semen Cuscutae CuscutachinensisLam..
Colla cornus cervi is that Cornu Cervi boils, concentrates the solid gum of making through decocting.
Colla Plastri Testudinis is that Carapax Et Plastrum Testudinis boils, concentrates the solid gum of making through decocting.
Radix Rehmanniae Preparata is the process of preparing Chinese medicine processed goods of Radix Rehmanniae.
Fructus Ligustri Lucidi is the dry mature fruit of Oleaceae plant Fructus Ligustri Lucidi LigustrumlucidumAit..
Radix Polygoni Multiflori Preparata is the process of preparing Chinese medicine processed goods of Radix Polygoni Multiflori.
Particularly, the compound preparation of treatment primary osteoporosis of the present invention, make by effective ingredient and excipient substance, it is characterized in that described effective ingredient is made up of the crude drug component of following weight portion ratio range: Fructus Lycii 30～20, Fructus Corni 30～20, Rhizoma Dioscoreae 30～20, Semen Cuscutae 30～20, Colla cornus cervi 30～20, Colla Plastri Testudinis 30～20, big Radix Rehmanniae Preparata 45～30, Fructus Ligustri Lucidi 45～30, Radix Polygoni Multiflori Preparata 45～30.
Among the present invention, preferred weight part proportioning of described crude drug is: Fructus Lycii 25～15, Fructus Corni 25～15, Rhizoma Dioscoreae 25～15, Semen Cuscutae 25～15, Colla cornus cervi 25～15, Colla Plastri Testudinis 25～15, big Radix Rehmanniae Preparata 38～22, Fructus Ligustri Lucidi 38～22, Radix Polygoni Multiflori Preparata 38～22.
Among the present invention, the more preferably weight portion proportioning of described crude drug is: Fructus Lycii 20～10, Fructus Corni 20～10, Rhizoma Dioscoreae 20～10, Semen Cuscutae 20～10, Colla cornus cervi 20～10, Colla Plastri Testudinis 20～10, big Radix Rehmanniae Preparata 30～15, Fructus Ligustri Lucidi 30～15, Radix Polygoni Multiflori Preparata 30～15.
The effective ingredient process ethanol of compound preparation of the present invention or aqueous solvent extraction and precipitate with ethanol, filterable method purification, wherein the extracting method that is adopted is the physicochemical property according to effective ingredient in the medicine, selects precipitate with ethanol, filterable extraction solvent and extraction conditions for use; The purification process that is adopted selects for use ethanol precipitation through the row purification process under the prerequisite that guarantees curative effect.
The invention provides the preparation method of above-mentioned compound preparation.
Compound preparation of the present invention prepares by following method and step:
1. take by weighing each medical material by prescription weight, soak 1h, decoct 1～3 time, decoct 0.5～1.5h at every turn, one fries in shallow oil and adds 10～14 times in water, and two, three fry in shallow oil 6～10 times of amount of water, merges decoction liquor, filter, under 60～70 ℃ of temperature, it is 1.05～1.30 extractum that filtrate is concentrated into relative density.Wherein, preferably decoct 2 times, decoct 1h at every turn, one fries in shallow oil and adds 14 times in water, and two fry in shallow oil 10 times of amount of water, merges decoction liquor, filters, and it is 1.05～1.07 extractum liquid that preferred filtered solution is concentrated into relative density;
2. add ethanol in the above-mentioned 1. extractum liquid, to concentration of alcohol be 50%～80%, preferably adding ethanol to concentration is 60%; Standing over night, precipitate with ethanol.Filter, filtrate is reclaimed ethanol under 60～70 ℃ of temperature, and to be concentrated into relative density be 1.35～1.40 equivalent extract;
3. above-mentioned 2. equivalent extract is drying under reduced pressure in the time of 70～80 ℃, is ground into fine powder, crosses 60 mesh sieves, promptly gets the extract powder of drug component of the present invention;
4. according to extract powder: filler: disintegrating agent=12: 5: 1 part by weight proportionings (cross-linked carboxymethyl cellulose is received for extract powder, microcrystalline Cellulose 101), get the above-mentioned component that 3. is worth, add filler, the disintegrating agent of aforementioned proportion.Mixing adopts dry granulation, and compacting is wrapped film-coat in flakes, makes finished tablet, promptly.
The preparation method of medicine activity component of the present invention, water extraction method and preferred decoction number of times, time and amount of water have been adopted, and the density of preferred precipitate with ethanol and concentration of alcohol are through row precipitate with ethanol purification, effective component extracting and remove impurity to greatest extent, concentrated, dry under the decompression cryogenic conditions, simultaneously to adjuvant, method of granulating and the condition etc. of drying means and condition, preparations shaping technology through row examination, screening, optimize and be suitable for industrialized preparation technology.
Compound preparation of the present invention can be made various oral formulations according to a conventional method, comprises tablet, granule, capsule, mixture, powder etc.
Among the present invention, described adjuvant is medicinal specification adjuvant, comprises dextrin, lactose, sodium bicarbonate, citric acid, Sodium Hydroxymethyl Stalcs, micropowder silica gel, starch, soluble starch, Polyethylene Glycol or magnesium stearate.
The interim decoction before compound preparation of the present invention can avoid Chinese medicine decoction to take, put for a long time and easily mouldly lose rotten and bring a lot of inconveniences to the patient, physicochemical property according to main flavour of a drug in clinical application characteristics, the preservation prescription, in conjunction with modern preparation technique, make solid preparations such as granule, tablet, capsule, powder, satisfy patient's demand easily and effectively.
The present invention has carried out zoopery, and 30 6 monthly age ICR female mices are divided into sham operated rats, model group, tonifying kidney-yin side's treatment group (latter is preparation of the present invention, also claims the treatment group) at random.The Micro-CT testing result shows in zooperal body, and high-caliber bone resorption and bone formation that tonifying kidney-yin can make oophorectomize cause all reduce, and makes it to return to the poised state of a kind of bone formation greater than bone resorption, thereby causes the increase of bone amount; HE dyeing detects in zooperal body, and the result is consistent with Micro-CT, shows the therapeutical effect of tonifying kidney-yin side to rats with osteoporosis; The immunohistochemical staining testing result shows that there is the excretory effect of the Bone Gla protein of promotion tonifying kidney-yin side; External former generation mesenchymal stem cells MSCs (BMSCs) testing result shows that there is the ability that is suppressed to the adipose cell differentiation tonifying kidney-yin side.
Description of drawings
Fig. 1 is a Micro-CT testing result in the zooperal body.
Fig. 2 is a HE dyeing testing result in the zooperal body.
Fig. 3 is OC (Osteocalcin) immunohistochemical staining testing result in the zooperal body.
Fig. 4 is zooperal external former generation mesenchymal stem cells MSCs (BMSCs) testing result.
Fig. 5 is the active testing result of ALP.
The specific embodiment
Embodiment 1
Take off row raw materials in weight portion medicine: Fructus Lycii 30～20, Fructus Corni 30～20, Rhizoma Dioscoreae 30～20, Semen Cuscutae 30～20, Colla cornus cervi 30～20, Colla Plastri Testudinis 30～20, big Radix Rehmanniae Preparata 45～30, Fructus Ligustri Lucidi 45～30, Radix Polygoni Multiflori Preparata 45～30, soak 1h, decoct 1～3 time, each 0.5～1.5h that decocts, one fries in shallow oil and adds 10～14 times in water, and two, three fry in shallow oil 6～10 times of amount of water, merge decoction liquor, filter, under 60～70 ℃ of temperature, it is 1.05～1.30 extractum that filtrate is concentrated into relative density;
2. add ethanol in the above-mentioned 1. extractum liquid, to concentration of alcohol be 50%～80%, standing over night, precipitate with ethanol.Filter, filtrate is reclaimed ethanol under 60～70 ℃ of temperature, and to be concentrated into relative density be 1.35～1.40 equivalent extract;
3. above-mentioned 2. equivalent extract is drying under reduced pressure in the time of 70～80 ℃, is ground into fine powder, crosses 60 mesh sieves, gets the extract powder of drug component;
4. according to extract powder: filler: disintegrating agent=12: 5: 1 part by weight proportionings (cross-linked carboxymethyl cellulose is received for extract powder, microcrystalline Cellulose 101), get the above-mentioned component that 3. is worth, add filler, the disintegrating agent of aforementioned proportion.Mixing adopts dry granulation, and compacting is wrapped film-coat in flakes, makes finished tablet, promptly.Or make various oral formulations according to a conventional method, comprise tablet, granule, capsule, mixture, powder etc.
Embodiment 2
Take off and state weight portion proportioning crude drug: Fructus Lycii 25～15, Fructus Corni 25～15, Rhizoma Dioscoreae 25～15, Semen Cuscutae 25～15, Colla cornus cervi 25～15, Colla Plastri Testudinis 25～15, big Radix Rehmanniae Preparata 38～22, Fructus Ligustri Lucidi 38～22, Radix Polygoni Multiflori Preparata 38～22.Soak 1h, decocts 2 times, decoct 1h at every turn, one fries in shallow oil and adds 14 times in water, and two fry in shallow oil 10 times of amount of water, merge decoction liquor, filtration, and it is 1.05～1.07 extractum liquid that filtered solution is concentrated into relative density;
2. add ethanol in the above-mentioned 1. extractum liquid, to concentration of alcohol be 60%; Standing over night, precipitate with ethanol.Filter, filtrate is reclaimed ethanol under 60～70 ℃ of temperature, and to be concentrated into relative density be 1.35～1.40 equivalent extract;
3. above-mentioned 2. equivalent extract is drying under reduced pressure in the time of 70～80 ℃, is ground into fine powder, crosses 60 mesh sieves, gets the extract powder of drug component;
4. according to extract powder: filler: disintegrating agent=12: 5: 1 part by weight proportionings (cross-linked carboxymethyl cellulose is received for extract powder, microcrystalline Cellulose 101), get the above-mentioned component that 3. is worth, add filler, the disintegrating agent of aforementioned proportion.Mixing adopts dry granulation, and compacting is wrapped film-coat in flakes, makes finished tablet, promptly.
Embodiment 3
Take off and state weight portion proportioning crude drug: Fructus Lycii 20～10, Fructus Corni 20～10, Rhizoma Dioscoreae 20～10, Semen Cuscutae 20～10, Colla cornus cervi 20～10, Colla Plastri Testudinis 20～10, big Radix Rehmanniae Preparata 30～15, Fructus Ligustri Lucidi 30～15, Radix Polygoni Multiflori Preparata 30～15, soak 1h, decoct 2 times, each 1h that decocts, one fries in shallow oil and adds 14 times in water, and two fry in shallow oil 10 times of amount of water, merges decoction liquor, filter, it is 1.05～1.07 extractum liquid that filtered solution is concentrated into relative density;
2. add ethanol in the above-mentioned 1. extractum liquid, to concentration of alcohol be 60%; Standing over night, precipitate with ethanol.Filter, filtrate is reclaimed ethanol under 60～70 ℃ of temperature, and to be concentrated into relative density be 1.35～1.40 equivalent extract;
3. above-mentioned 2. equivalent extract is drying under reduced pressure in the time of 70～80 ℃, is ground into fine powder, crosses 60 mesh sieves, gets the extract powder of drug component;
4. according to extract powder: filler: disintegrating agent=12: 5: 1 part by weight proportionings (cross-linked carboxymethyl cellulose is received for extract powder, microcrystalline Cellulose 101), get the above-mentioned component that 3. is worth, add filler, the disintegrating agent of aforementioned proportion.Mixing adopts dry granulation, and compacting is wrapped film-coat in flakes, makes finished tablet, promptly.
Embodiment 4 zooperies
30 6 monthly age ICR female mices are divided into sham operated rats, model group, tonifying kidney-yin side's treatment group (preparation of the present invention at random.Also claim the treatment group).Model group and treatment group excision bilateral ovaries, sham operated rats spay peripheral part fatty tissue.The treatment group began by 0.5ml/ gastric infusion in modeling on the 4th day.Continuous medicine-filling drug withdrawal one day after 2 days, this scheme lasted till the 90th day.Put to death mice in 90 days after the modeling, get the 4th lumbar vertebra and carry out Micro-CT scanning, estimate the bone amount and change situation.Adopt full bone marrow adhere-wall culture method to cultivate former generation BMSCs, observe spontaneous one-tenth fat differentiation number.
Carry out Micro-CT detection in the zooperal body:
Model group is compared with sham operated rats, bone norphometry mathematic(al) parameter bone density (BMD), the ratio of the volume of bone trabecular volume and sample (BV/TV), bone trabecula quantity (Tb.N), bone trabecula thickness (Tb.Th) all obviously reduces, and bone trabecula gap (Tb.Sp) obviously increases (p all＜0.01).
Tonifying kidney-yin side's treatment group Connection Density (Conn.D.) of comparing with model group, bone trabecula thickness (Tb.Th) obviously increases, and bone trabecula gap (Tb.Sp) obviously reduces (p is all＜0.01).Bone density (BMD), the ratio of the volume of bone trabecular volume and sample (BV/TV), bone trabecula quantity (Tb.N) all has the trend of improvement, but does not have significant difference.(as shown in Figure 1), the result shows that high-caliber bone resorption and bone formation that tonifying kidney-yin can make oophorectomize cause all reduce, and makes it to return to the poised state of a kind of bone formation greater than bone resorption, thereby causes the increase of bone amount.
Carry out HE dyeing detection in the zooperal body:
Sham operated rats bone trabecula thickness unanimity is evenly distributed, and not seeing has phenomenon of rupture, model group and sham operated rats are relatively, cortical bone attenuation, medullary cavity enlarge, bone trabecula attenuate distribute sparse, phenomenon of rupture is arranged, tonifying kidney-yin side compares with model group, and the bone trabecula number obviously increases, with sham operated rats trabecular bone structure basic identical (as shown in Figure 2), the painted result of HE is consistent with Micro-CT, and the therapeutical effect of tonifying kidney-yin side to rats with osteoporosis is described.
Carry out OC (Osteocalcin) immunohistochemical staining detection in the zooperal body:
OC (Osteocalcin) Bone Gla protein, it is by osteoblast secretion and is accumulated in the osteocyte epimatrix, is considered to one of relevant with bone formation sensitive indicator.Sham operated rats is strong positive dyeing, and the positive staining of model group weakens relatively, and tonifying kidney-yin side's positive staining strengthens, and bone trabecula dyeing dark (as shown in Figure 3), illustrate that there is the excretory effect of promotion Bone Gla protein tonifying kidney-yin side.
Carrying out zooperal external former generation mesenchymal stem cells MSCs (BMSCs) detects:
Fat drop is used to measure the lipoblast differentiation of BMSCs.Drew materials the 7th day that cultivates in former generation, the fat drop number of comparing the model group of model group with normal group obviously increases, and the fat drop digital display of tonifying kidney-yin side work reduces (as shown in Figure 4);
The ALP activity is osteoplastic early stage indicant, is used to measure the osteoblast differentiation of BMSCs.Drew materials the 9th day that cultivates in former generation, the positive performance of model seldom has positive performance to increase (as shown in Figure 5) greatly in tonifying kidney-yin side's treatment group in the normal culture medium
This experimental result shows, the lipoblast of model group increases and the osteoblast minimizing, change relevant with the precursor MSCs of lipotrophy and osteoblast and adipose cell to both interactive relations of differentiation based on the minimizing of bone amount, therefore, show that compound preparation of the present invention has the ability that is suppressed to the adipose cell differentiation.
Claims (7)
1. compound preparation for the treatment of primary osteoporosis, form by effective ingredient and pharmaceutical carrier, it is characterized in that described effective ingredient is made up of following raw materials in weight portion medicine component: Fructus Lycii 30～20, Fructus Corni 30～20, Rhizoma Dioscoreae 30～20, Semen Cuscutae 30～20, Colla cornus cervi 30～20, Colla Plastri Testudinis 30～20, big Radix Rehmanniae Preparata 45～30, Fructus Ligustri Lucidi 45～30, Radix Polygoni Multiflori Preparata 45～30.
2. press the compound preparation of the described treatment primary osteoporosis of claim 1, it is characterized in that the weight portion proportioning of described crude drug is: Fructus Lycii 25～15, Fructus Corni 25～15, Rhizoma Dioscoreae 25～15, Semen Cuscutae 25～15, Colla cornus cervi 25～15, Colla Plastri Testudinis 25～15, big Radix Rehmanniae Preparata 38～22, Fructus Ligustri Lucidi 38～22, Radix Polygoni Multiflori Preparata 38～22.
3. by the compound preparation of the described treatment primary osteoporosis of claim 1, it is characterized in that the weight portion proportioning of described crude drug is: Fructus Lycii 20～10, Fructus Corni 20～10, Rhizoma Dioscoreae 20～10, Semen Cuscutae 20～10, Colla cornus cervi 20～10, Colla Plastri Testudinis 20～10, big Radix Rehmanniae Preparata 30～15, Fructus Ligustri Lucidi 30～15, Radix Polygoni Multiflori Preparata 30～15.
4. the preparation method of claim 1 or 2 or 3 described treatment primary osteoporosis compound preparations is characterized in that by following method and step:
1. take by weighing each medical material by the prescription weight portion, soak 1h, decoct 1～3 time, decoct 0.5～1.5h at every turn, one fries in shallow oil and adds 10～14 times in water, and two, three fry in shallow oil 6～10 times of amount of water, merges decoction liquor, filter, under 60～70 ℃ of temperature, it is 1.05～1.30 extractum that filtrate is concentrated into relative density;
2. add ethanol in the above-mentioned 1. extractum liquid, to concentration of alcohol be 50%～80%, standing over night, precipitate with ethanol filters, filtrate is reclaimed ethanol under 60～70 ℃ of temperature, and to be concentrated into relative density be 1.35～1.40 equivalent extract;
3. above-mentioned 2. equivalent extract is drying under reduced pressure in the time of 70～80 ℃, is ground into fine powder, crosses 60 mesh sieves, gets extract powder;
4. by extract powder: filler: disintegrating agent is 12: 5: 1 weight ratios, gets the above-mentioned extract powder that 3. makes, and adds filler, disintegrating agent, and mixing adopts dry granulation, and compacting in flakes; Or the bag film-coat, make finished tablet.
5. method according to claim 4 is characterized in that described filler is a microcrystalline Cellulose 101; Described disintegrating agent is a cross-linking sodium carboxymethyl cellulose.
6. method according to claim 4 is characterized in that described step 1., gets each medical material, soaks 1h, decoct 2 times, decoct 1h at every turn, one fries in shallow oil and adds 14 times in water, and two fry in shallow oil 10 times of amount of water, merge decoction liquor, filter, it is 1.05～1.07 extractum liquid that filtered solution is concentrated into relative density.
7. method according to claim 4 is characterized in that described step 2., and to add ethanol to concentration be 60%, reclaims the extract behind the ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210020005.1A CN103211948B (en) | 2012-01-21 | 2012-01-21 | A kind of compound preparation for the treatment of primary osteoporosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210020005.1A CN103211948B (en) | 2012-01-21 | 2012-01-21 | A kind of compound preparation for the treatment of primary osteoporosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103211948A true CN103211948A (en) | 2013-07-24 |
| CN103211948B CN103211948B (en) | 2015-10-21 |
Family
ID=48810334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210020005.1A Active CN103211948B (en) | 2012-01-21 | 2012-01-21 | A kind of compound preparation for the treatment of primary osteoporosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103211948B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147906A (en) * | 2015-10-09 | 2015-12-16 | 武素艳 | Traditional Chinese medicine for treating primary osteoporosis caused by qi deficiency of spleen and stomach and preparation method of traditional Chinese medicine |
| CN107349333A (en) * | 2017-07-27 | 2017-11-17 | 北华大学 | Composition with increase bone density effect and its preparation method and application |
| CN109700918A (en) * | 2019-01-29 | 2019-05-03 | 上海市杨浦区中心医院(同济大学附属杨浦医院) | Traditional Chinese medicine composition for treating postmenopausal osteoporosis |
| CN111560307A (en) * | 2020-05-26 | 2020-08-21 | 劲牌有限公司 | Maca health wine and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184657A (en) * | 2016-03-15 | 2017-09-22 | 上海中医药大学附属龙华医院 | It is a kind of to treat compound Chinese medicinal preparation of primary osteoporosis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048932A (en) * | 2009-10-28 | 2011-05-11 | 王宝凤 | Formula of traditional Chinese medicine for treating postmenopausal osteoporosis |
-
2012
- 2012-01-21 CN CN201210020005.1A patent/CN103211948B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048932A (en) * | 2009-10-28 | 2011-05-11 | 王宝凤 | Formula of traditional Chinese medicine for treating postmenopausal osteoporosis |
Non-Patent Citations (3)
| Title |
|---|
| 秦腊梅等: "4味中药对体外培养成骨样细胞增殖的影响――对通补强骨方中主要组成药物的研究", 《中国实验方剂学杂志》 * |
| 陈少茹等: "何首乌防治骨质疏松症的研究进展", 《现代医药卫生》 * |
| 鞠大宏等: "左归丸对去卵巢所致大鼠骨质疏松症的治疗作用", 《中国中医基础医学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147906A (en) * | 2015-10-09 | 2015-12-16 | 武素艳 | Traditional Chinese medicine for treating primary osteoporosis caused by qi deficiency of spleen and stomach and preparation method of traditional Chinese medicine |
| CN107349333A (en) * | 2017-07-27 | 2017-11-17 | 北华大学 | Composition with increase bone density effect and its preparation method and application |
| CN107349333B (en) * | 2017-07-27 | 2020-07-17 | 北华大学 | Composition with effect of increasing bone mineral density and preparation method and application thereof |
| CN109700918A (en) * | 2019-01-29 | 2019-05-03 | 上海市杨浦区中心医院(同济大学附属杨浦医院) | Traditional Chinese medicine composition for treating postmenopausal osteoporosis |
| CN111560307A (en) * | 2020-05-26 | 2020-08-21 | 劲牌有限公司 | Maca health wine and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103211948B (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068625B (en) | Traditional Chinese medicinal composition for reducing blood sugar and blood pressure and preparation method thereof | |
| CN102764339B (en) | Maca composition for improving sexual dysfunction and preparation method and application thereof | |
| CN103211948B (en) | A kind of compound preparation for the treatment of primary osteoporosis and preparation method thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN103041100A (en) | Traditional Chinese medicine preparation for treatment of hypomenorrhea and preparation method thereof | |
| CN104825528B (en) | Have effects that increase the composition and its preparation method and application of bone density | |
| CN102302609A (en) | Compound traditional Chinese drug preparation for improving subhealth | |
| CN104906366A (en) | Pharmaceutical preparation for treating delayed menorrhea | |
| CN102114070B (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN103735871A (en) | Chinese medicinal composition for treating neurasthenia and preparation method thereof | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN102885953A (en) | Traditional Chinese medicine preparation for tonifying kidney and spleen and preparation process thereof | |
| CN107184657A (en) | It is a kind of to treat compound Chinese medicinal preparation of primary osteoporosis and preparation method thereof | |
| CN104958662A (en) | Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof | |
| CN104998225A (en) | Medicinal preparation for treatment of constipation | |
| CN104721528A (en) | Traditional Chinese medicine composition for nourishing yin and blood, tonifying heart and soothing nerves and preparation method thereof | |
| CN102552583A (en) | Compound calming oral preparation and preparation method thereof | |
| CN102008587A (en) | Chinese medicinal preparation for treating liver cancer and preparation method thereof | |
| CN106309636B (en) | Pharmaceutical composition for uterine bleeding | |
| CN103690834A (en) | Antihypertensive traditional Chinese medicinal composition and preparation method thereof | |
| CN116549585A (en) | Medicine for treating thyroid nodule and preparation method thereof | |
| CN102139091B (en) | Pharmaceutical composition for preventing or treating abortion | |
| CN103405554A (en) | Bowel clearing medicine before abdominal operation | |
| CN102370838A (en) | Kidney-invigorating and tendon-reinforcing double-phase capsule | |
| CN101164608A (en) | Traditional Chinese medicine composition for treating high blood pressure and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yongjun Inventor after: Shi Qi Inventor after: Jia Youji Inventor after: Li Xiaofeng Inventor after: Wang Hongshen Inventor after: Yang Zhu Inventor after: Bian Qin Inventor after: Xu Hao Inventor after: Yang Zhou Inventor after: Tang Dezhi Inventor after: Yang Feng Inventor after: Zhao Yongjian Inventor after: Liu Shufen Inventor before: Wang Yongjun Inventor before: Shi Qi Inventor before: Yang Zhu Inventor before: Bian Qin Inventor before: Xu Hao Inventor before: Yang Zhou Inventor before: Tang Dezhi Inventor before: Yang Feng Inventor before: Zhao Yongjian Inventor before: Liu Shufen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG YONGJUN YANG ZHU BIAN QIN XU HAO YANG ZHOU TANG DEZHI YANG FENG ZHAO YONGJIAN LIU SHUFEN SHI QI TO: WANG YONGJUN YANG ZHU BIAN QIN XU HAO YANG ZHOU TANG DEZHI YANG FENG ZHAO YONGJIAN LIU SHUFEN SHI QI JIA YOUJI LI XIAOFENG WANG HONGSHEN |
|
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yongjun Inventor after: Shi Qi Inventor after: Jia Youji Inventor after: Li Xiaofeng Inventor after: Wang Hongshen Inventor after: Yao Min Inventor after: Qiao Liang Inventor after: Yang Zhu Inventor after: Bian Qin Inventor after: Xu Hao Inventor after: Yang Zhou Inventor after: Tang Dezhi Inventor after: Yang Feng Inventor after: Zhao Yongjian Inventor after: Liu Shufen Inventor before: Wang Yongjun Inventor before: Shi Qi Inventor before: Jia Youji Inventor before: Li Xiaofeng Inventor before: Wang Hongshen Inventor before: Yang Zhu Inventor before: Bian Qin Inventor before: Xu Hao Inventor before: Yang Zhou Inventor before: Tang Dezhi Inventor before: Yang Feng Inventor before: Zhao Yongjian Inventor before: Liu Shufen |
|
| COR | Change of bibliographic data |